Beleave Inc. (CSE:BE), a diversified biotech company with a purpose-built ACMPR licensed cannabis facility in Hamilton, Ontario and patient services clinics operating across Ontario under the Medi-Green brand, today announced the launch of an expanded shareholder communications initiative designed to provide improved visibility into Beleave’s current and planned operations.  The initiative was prompted by an increase in shareholder inquiries, the Company’s desire for increased transparency for its stakeholders and the recent growth in its operations, highlighted by both the acquisition of the Medi-Green patient services business and receipt of its ACMPR sales license. 

“The initiative is a multi-channel approach,” commented Beleave CEO Andrew Wnek, “As the industry continues to grow we feel that increasing our visibility in a transparent fashion will not only add comfort to our respected shareholder base but allow for productive discussion between shareholders and company management.”

The program is comprehensive and includes a redesign of the corporate website, the development of the investor relations portal, consistent shareholder update videos, quarterly investor conference calls with Company management, an active blog with in-house contributors, and an expanded social media strategy.  In order execute on the aforementioned programs, the Company will seek to increase its shareholder communications with the launch of new features each month.  The corporate website will include a new investor relations newsroom which will include real time press release dissemination, an active corporate blog featuring industry trends, XBRL data, and automatic posting of public filings. The newsroom will also feature corporate videos including consistent shareholder update videos featuring officers, directors and key personnel.

In support of its shareholder relations initiative, the Company retained two leading corporate communications firms, Storyboard Communications and, most recently, Link Media. Both firms act at arm’s length to the Company and are paid a monthly cash retainer or per published PR piece. To the knowledge of the Company, neither Storyboard nor Link Media owns any of the Company’s securities.  Further, beyond those transactions disclosed on, the Company has no knowledge of any directors trading the Companies securities within the last 90 days.  Since the beginning of May, Link Media has arranged for dissemination of two third party research articles independent from the Company while allowing the Company to retain editorial control to ensure consistency across all articles and the monitor that published material was derived from the Company’s public filings on  “Rolling out this type of program will allow the Company to have consistent, relevant news flow allowing investors to digest information in multiple ways,” continued Wnek. “In the long run this consistent news flow should play a role in combating short-selling common in the Cannabis industry.”

CSE Short information is published on a bi-weekly basis can be found at  The Company believes the primary reason for its recent positive share position to be a decrease in short-selling against and the Company’s shares recently receiving DTC eligibility on the OTCQX, rather than the impact of the s articles arranged by Link Media.

About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on

SOURCE Beleave Inc.

Click here to connect with Beleave Inc. (CSE:BE) and receive an Investors Presentation.


Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less